[US-헬스케어] 05/28 Wall St. Recap

Eli Lilly (LLY) continues to demonstrate robust momentum, underpinned by the explosive commercial success of its (obesity therapeutics), specifically Mounjaro and Zepbound. The company’s Q1 earnings report exceeded market expectations, validating its dominant position in the high-growth (GLP-1 receptor agonist) market.

While the stock’s valuation has reached premium levels, the long-term investment thesis remains intact, driven by a strong (pipeline expansion). The critical factor for sustained growth will be the successful development and commercialization of (oral obesity drugs), which would significantly broaden the addressable patient population and solidify its competitive moat against peers. Despite the recent price surge, the company’s fundamental growth trajectory justifies its current market leadership.

Novo Nordisk’s recent momentum is driven by the clinical and commercial validation of its oral Wegovy formulation. The ability to transition from injectable to oral delivery represents a significant competitive moat, potentially expanding the addressable market by improving patient adherence and reducing logistical burdens.

While the stock has experienced short-term volatility due to regulatory scrutiny regarding compounded drugs, the upward revision of financial guidance and EU regulatory backing signal strong underlying demand. We view the recent price recovery as a reflection of the market pricing in the long-term earnings growth potential of the oral GLP-1 segment, which effectively mitigates concerns over supply chain constraints and margin compression.

Amgen (AMGN) is currently navigating a period of heightened volatility, characterized by sharp daily price swings and conflicting market sentiment. While the company’s recent commitment of a (300 million USD investment) to expand its domestic manufacturing footprint signals a long-term commitment to (operational scaling) and supply chain resilience, the market remains cautious regarding its valuation.

Following a period of sustained stock appreciation, investors are now questioning whether the current (Discounted Cash Flow) valuation still offers an attractive entry point or if the stock has reached a plateau. The recent 4.69% decline following a 3.25% gain suggests that the stock is undergoing a (price discovery phase) as the market weighs the company’s robust pipeline against potential growth deceleration. Investors should monitor whether these capital expenditures translate into tangible margin expansion before committing further capital.

UnitedHealth Group (UNH) continues to demonstrate robust operational resilience and long-term value creation, as evidenced by its optimistic 2026 financial outlook. Despite recent volatility and the exit of high-profile institutional investors like Berkshire Hathaway, the market sentiment remains largely constructive, supported by strong analyst consensus and positive earnings momentum.

The company’s ability to maintain a compelling earnings narrative amidst regulatory and macroeconomic headwinds underscores its dominant position in the managed care sector. While the recent 30% rally necessitates a cautious valuation check, the underlying fundamental growth trajectory suggests that UNH remains a core holding for long-term investors seeking exposure to the healthcare services industry.

Pfizer (PFE) is currently undergoing a strategic pivot, transitioning from its pandemic-era reliance on COVID-19 products toward a diversified portfolio focused on vaccine innovation and hematology. The recent Q1 financial results, which surpassed market expectations, signal a stabilization in core business performance and improved operational efficiency.

Furthermore, the geopolitical landscape surrounding the PFE (Pfizer-BioNTech/US regulatory) framework—specifically regarding supply chain localization and regulatory shifts—is creating a ripple effect in global markets. While Pfizer strengthens its domestic production capabilities, the resulting regulatory environment is inadvertently benefiting non-Chinese supply chain participants, such as POSCO Future M, by reducing reliance on Chinese competitors. This shift underscores Pfizer’s role as a catalyst for broader industrial realignments, enhancing its investment case as it leverages its robust R&D pipeline to drive long-term growth.